Experimental models of lupus nephritis

Contributions to Nephrology

Volumn 169, Issue , 2011, Pages 183-197

  Grande, Joseph P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE;

ANIMAL; ARTICLE; B LYMPHOCYTE; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLISM; MOUSE; MOUSE MUTANT; T LYMPHOCYTE;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS NEPHRITIS; MICE; MICE, KNOCKOUT; T-LYMPHOCYTES;

EID: 79551538645     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000319241     Document Type: Article

References (141)

1. Peutz- Kootstra CJ, de Heer E, Hoedemaeker PJ, Abrass CK, Bruijn JA: Lupus nephritis: lessons from experimental animal models. J Lab Clin Med 2001;137:244-260.
2. Johnson AE, Gordon C, Palmer RG, Bacon PA: The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-558.
3. Grande JP, Balow JE: Renal biopsy in lupus nephritis. Lupus 1998;7:611-617.
4. Weening JJ, DAgati VD, Schwartz MM, et al: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004 ;15:241-250.
5. Grande JP: Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus 1998;7:604-610.
6. Mohan C, Datta SK: Lupus: key pathogenic mechanisms and contributing factors. Clin Immunol Immunopathol 1995;77:209-220.
7. Hahn BH: Antibodies to DNA. N Engl J Med 1998;338:1359-1368.
8. Berden J: Lupus nephritis. Kidney Int 1997;52:538-558.
9. Burlingame RW, Boey ML, Starkebaum G, Rubin RL: The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994;94:184-192.
10. Perkins DL, Glaser RM, Mahon CA, Michaelson J, Marshak- Rothstein A: Evidence for an intrinsic B cell defect in lpr/lpr mice apparent in neonatal chimeras. J Immunol 1990;145:549-555.
11. Sobel ES, Katagiri T, Katagiri K, Morris SC, Cohen PL, Eisenberg RA: An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J Exp Med 1991;173: 1441-1449.
12. Nemazee D, Guiet C, Buerki K, Marshak- Rothstein A: B lymphocytes from the autoimmune- prone mouse strain MLR/lpr manifest an intrinsic defect in tetraparental MRL/lpr in equilibrium DBA/2 chimeras. J Immunol 1991;147:2536-2539.
13. Mohan C, Adams S, Stanik V, Datta SK: Nucleosome: a major immunogen for pathogenic autoantibodyinducing T cells of lupus. J Exp Med 1993;177:1367-1381.
14. Madaio MP, Shlomchik MJ: Emerging concepts regarding B cells and autoantibodies in murine lupus nephritis. B cells have multiple roles; all autoantibodies are not equal. J Am Soc Nephrol 1996;7:387-396.
15. Couser WG: Mediation of immune glomerular injury. J Am Soc Nephrol 1990;1:13-29.
16. van Bruggen MC, Kramers C, Walgreen B, Elema JD, Kallenberg CG, van den Born J, et al: Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol Dial Transplant 1997;12:57-66.
17. Sabbaga J, Pankewycz OG, Lufft V, Schwartz RS, Madaio MP: Crossreactivity distinguishes serum and nephritogenic anti- DNA antibodies in human lupus from their natural counterparts in normal serum. J Autoimmunity 1990;3:215-235.
18. Foster MH, Cizman B, Madaio MP: Nephritogenic autoantibodies in systemic lupus erythematosus: Immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab Invest 1993;69: 494-507.
19. Couser WG: Mediation of immune glomerular injury. J Am Soc Nephrol 1990;1:13-29.
20. Eddy AA, Michael AF. Immunopathogenic mechanisms of glomerular injury; in Tisher CC, Brenner BM (eds): Renal Pathology. Philadelphia, J. B. Lippincott Co., 1994, pp 162- 221.
21. Hashimoto Y, Ziff M, Hurd ER: Increased endothelial cell adherence, aggregation, and superoxide generation by neutrophils incubated in systemic lupus erythematosus and Feltys syndrome sera. Arthritis Rheum 1982;25:1409-1418.
22. Lai KN, Leung JCK, Lai KB, Lai CKW: Effect of anti- DNA autoantibodies on the gene expression of interleukin 8, transforming growth factor- β, and nitric oxide synthase in cultured endothelial cells. Scand J Rheumatol 1997;26:461-467.
23. Tsai CY, Wu TH, Sun KH, Liao TS, Lin WM, Yu CL: Polyclonal IgG antidsDNA antibodies exert cytotoxic effect on cultured rat mesangial cells by binding to cell membrane and augmenting apoptosis. Scand J Rheumatol 1993;22:162-171.
24. Helyer BJ, Howie JB: Renal disease associated with positive lupus erythematosus tests in a cross- bred strain of mice. Nature 1963;197:197.
25. Bielschowsky M, Helyer B, Howie J: Spontaneous anemia in mice of the NZB/BL strain. Proc Univ Otago Med Sch 1959;37:9-11.
26. Andrews BS, Eisenberg RA, Theofilopoulos AN, et al: Spontaneous murine lupus- like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198-1215.
27. Stoll ML, Gavalchin J: Systemic lupus erythematosus- messages from experimental models. Rheumatology (Oxford) 2000;39:18-27.
28. Kelley VE, Winkelstein A: Age- and sex- related glomerulonephritis in New Zealand white mice. Clin Immunol Immunopathol 1980;16:142-150.
29. Hahn BH, Shulman LE: Autoantibodies and nephritis in the white strain (NZW) of New Zealand mice. Arthritis Rheum 1969;12:355-364.
30. Dubois EL, Horowitz RE, Demopoulos HB, Teplitz R: NZB/ NZW mice as a model of systemic lupus erythematosus. JAMA 1966;195:285-289.
31. Channing AA, Kasuga T, Horowitz RE, Dubois EL, Demopoulos HB: An ultrastructural study of spontaneous lupus nephritis in the NZB- BL- NZW mouse. Am J Pathol 1965;47: 677-694.
32. Burnet FM, Holmes MC: The natural history of the NZB/NZW F1 hybrid mouse: a laboratory model of systemic lupus erythematosus. Australas Ann Med 1965;14:185-191.
33. Howie JB, Helyer BJ: The immunology and pathology of NZB mice. Adv Immunol 1968;9:215-266.
34. Morel L, Wakeland EK: Susceptibility to lupus nephritis in the NZB/W model system. Curr Opin Immunol 1998;10:718-725.
35. Theofilopoulos AN, Dixon FJ: Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-390.
36. Murphy E, Roths J: A single gene for massive lymphoproliferation with immune complex disease in a new mouse strain. Proceedings of the 16th International Congress in Hematology Exerpta Medica, Amsterdam. 1976;69:69-80.
37. Itoh N, Yonehara S, Ishii A, et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243.
38. Cohen PL, Eisenberg RA: Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243-269.
39. Watanabe- Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-317.
40. Nagata S, Golstein P. The Fas death factor. Science. 1995 Mar 10;267(5203):1449-56.
41. Chan OT, Madaio MP, Shlomchik MJ: The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999;169:107-121.
42. Takahashi S, Nose M, Sasaki J, Yamamoto T, Kyogoku M: IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis. J Immunol 1991;147:515-519.
43. Teramoto K, Negoro N, Kitamoto K, et al: Microarray analysis of glomerular gene expression in murine lupus nephritis. J Phar macol Sci 2008;106:56-67.
44. Mysler E, Bini P, Drappa J, et al: The apoptosis- 1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994;93:1029-1034.
45. Fisher GH, Rosenberg FJ, Straus SE, et al: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-946.
46. Rieux- Laucat F, Le Deist F, Hivroz C, et al: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-1349.
47. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S: Autoreactive B cell responses to RNA- related antigens due to TLR7 gene duplication. Science 2006;312:1669-1672.
48. Subramanian S, Tus K, Li QZ, et al: A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006;103:9970-9975.
49. Florquin S, Abramowicz D, de Heer E, et al: Renal immunopathology in murine host- versus- graft disease. Kidney Int 1991;40:852-861.
50. Santiago- Raber ML, Laporte C, Reininger L, Izui S: Genetic basis of murine lupus. Autoimmun Rev 2004;3(1):33-39.
51. Fairhurst AM, Wandstrat AE, Wakeland EK: Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 2006;92:1-69.
52. Jorgensen TN, Gubbels MR, Kotzin BL: New insights into disease pathogenesis from mouse lupus genetics. Curr Opin Immunol 2004;16:787-793.
53. Mohan C, Alas E, Morel L, Yang P, Wakeland EK: Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/ DNA subnucleosomes. J Clin Invest 1998;101:1362-1372.
54. Mohan C, Morel L, Yang P, Wakeland EK: Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J Immunol 1997;159:454-465.
55. Mohan C, Yu Y, Morel L, Yang P, Wakeland EK: Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J Immunol 1999;162:6492-6502.
56. Hicks J, Bullard DC: Review of autoimmune (lupus- like) glomerulonephritis in murine models. Ultrastruct pathol 2006;30:345-359.
57. Wu X, Jiang N, Deppong C, et al: A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J Immunol 2002;169:1587-1592.
58. Jiang Y, Hirose S, Abe M, et al: Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 2000;51:429-435.
59. Pritchard NR, Cutler AJ, Uribe S, Chadban SJ, Morley BJ, Smith KG: Autoimmune- prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII. Curr Biol 2000;10:227-230.
60. Cunninghame Graham DS, Vyse TJ: The candidate gene approach: have murine models informed the study of human SLE? Clin Exp Immunol 2004;137:1-7.
61. Vlahakos D, Foster MH, Ucci AA, Barrett KJ, Datta SK, Madaio MP: Murine monoclonal anti- DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol 1992;2:1345-1354.
62. Mevorach D, Zhou JL, Song X, Elkon KB: Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998;188:387-392.
63. Georgiev M, Agle LM, Chu JL, Elkon KB, Ashany D: Mature dendritic cells readily break tolerance in normal mice but do not lead to disease expression. Arthritis Rheum 2005;52:225-238.
64. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I: Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-351.
65. Arbuckle MR, McClain MT, Rubertone MV, et al: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-1533.
66. Levine JS, Subang R, Nasr SH, et al: Immunization with an apoptotic cell- binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J Immunol 2006; 177:6504-6516.
67. Mjelle JE, Kalaaji M, Rekvig OP: Exposure of chromatin and not high affinity for dsDNA determines the nephritogenic impact of anti- dsDNA antibodies in (NZBxNZW)F1 mice. Autoimmunity 2009;42:104-111.
68. Mortensen ES, Rekvig OP: Nephritogenic potential of anti- DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 2009;20:696-704.
69. Wen ZK, Xu W, Xu L, et al: DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus- like autoimmune disease in SLE- non- susceptible mice. Rheumatology (Oxford) 2007;46:1796-1803.
70. Santiago- Raber ML, Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun. 2009 Nov- Dec;33(3- 4):231-238.
71. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL: Treatment of lupus- prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007;37:3582-3586.
72. Savarese E, Steinberg C, Pawar RD, et al: Requirement of Toll- like receptor 7 for pristane- induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 2008;58:1107-1115.
73. Sadanaga A, Nakashima H, Akahoshi M, et al: Protection against autoimmune nephritis in MyD88- deficient MRL/lpr mice. Arthritis Rheum 2007;56:1618-1628.
74. Anders H-J, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, et al: Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 2004 January 20, 2004:03-0646fje.
75. Deane JA, Pisitkun P, Barrett RS, et al: Control of Toll- like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007;27:801-810.
76. Yasutomo K, Horiuchi T, Kagami S, et al: Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 2001;28:313-314. (Pubitemid 32702418)
77. Mannherz HG, Peitsch MC, Zanotti S, Paddenberg R, Polzar B: A new function for an old enzyme: the role of DNase I in apoptosis. Curr Top Microbiol Immunol 1995;198:161-174.
78. Jacob M, Napirei M, Ricken A, Dixkens C, Mannherz HG: Histopathology of lupus- like nephritis in Dnase1- deficient mice in comparison to NZB/W F1 mice. Lupus 2002; 11:514-527.
79. Bruns A, Blass S, Hausdorf G, Burmester GR, Hiepe F: Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 2000;43:2307-2315.
80. Jacob L, Viard JP: Anti- DNA antibodies and their relationships with anti- histone and anti- nucleosome specificities. Eur J Med 1992;1:425-431.
81. Seredkina N, Zykova SN, Rekvig OP: Progression of murine lupus nephritis is linked to acquired renal Dnase1 deficiency and not to up- regulated apoptosis. Am J Pathol 2009;175:97-106.
82. Herrmann M, Winkler T, Gaipl U, Lorenz H, Geiler T, Kalden JR: Etiopathogenesis of systemic lupus erythematosus. Int Arch Allergy Immunol 2000;123:28-35.
83. Walport MJ: Lupus, DNase and defective disposal of cellular debris. Nat Genet 2000;25:135-136.
84. Strasser A, Whittingham S, Vaux DL, et al: Enforced BCL2 expression in B- lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991;88:8661-8665.
85. Kuo P, Bynoe MS, Wang C, Diamond B: Bcl- 2 leads to expression of anti- DNA B cells but no nephritis: a model for a clinical subset. Eur J Immunol 1999;29:3168-3178.
86. Di Cristofano A, Kotsi P, Peng YF, Cordon- Cardo C, Elkon KB, Pandolfi PP: Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999;285:2122-2125.
87. Van Parijs L, Refaeli Y, Abbas AK, Baltimore D: Autoimmunity as a consequence of retrovirus- mediated expression of C- FLIP in lymphocytes. Immunity 1999;11:763-770.
88. Zhao Z, Burkly LC, Campbell S, et al: TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graftversus- host model of systemic lupus erythematosus. J Immunol 2007;179: 7949-7958.
89. Molano A, Lakhani P, Aran A, Burkly LC, Michaelson JS, Putterman C: TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett 2009;125:119-128.
90. Birmingham DJ, Rovin BH, Yu CY, Hebert LA: Of mice and men: the relevance of the mouse to the study of human SLE. Immunol Res 2001;24:211-224.
91. Slingsby JH, Norsworthy P, Pearce G, et al: Homozygous hereditary C1q deficiency and systemic lupus erythematosus. A new family and the molecular basis of C1q deficiency in three families. Arthritis Rheum 1996;39:663-670.
92. Casciola- Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-1330.
93. Walport MJ: Complement and systemic lupus erythematosus. Arthritis Res 2002;4 (Suppl 3):S279-S293.
94. Walport MJ, Davies KA, Botto M: C1q and systemic lupus erythematosus. Immunobiology 1998;199:265-285.
95. Mitchell DA, Pickering MC, Warren J, et al: C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 2002;168:2538-2543.
96. Botto M, DellAgnola C, Bygrave AE, et al: Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-59.
97. Rupert KL, Moulds JM, Yang Y, et al: The molecular basis of complete complement C4A and C4B deficiencies in a systemic lupus erythematosus patient with homozygous C4A and C4B mutant genes. J Immunol 2002;169:1570-1578.
98. Sullivan KE, Petri MA, Schmeckpeper BJ, McLean RH, Winkelstein JA: Prevalence of a mutation causing C2 deficiency in systemic lupus erythematosus. J Rheumatol 1994;21:1128-1133.
99. Bao L, Haas M, Boackle SA, et al: Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002;168:3601-3607.
100. Marsh CB, Wewers MD, Tan LC, Rovin BH: Fc(gamma) receptor crosslinking induces peripheral blood mononuclear cell monocyte chemoattractant protein- 1 expression: role of lymphocyte Fc(gamma)RIII. J Immunol 1997;158:1078-1084.
101. Marsh CB, Anderson CL, Lowe MP, Wewers MD: Monocyte IL- 8 release is induced by two independent Fc gamma R- mediated pathways. J Immunol 1996;157:2632-2637.
102. Clynes R, Dumitru C, Ravetch JV: Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998;279:1052-1054.
103. Benschop RJ, Cambier JC: B cell development: signal transduction by antigen receptors and their surrogates. Curr Opin Immunol 1999;11:143-151.
104. Cornall RJ, Cyster JG, Hibbs ML, et al: Polygenic autoimmune traits: Lyn, CD22, and SHP- 1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998;8:497-508.
105. Tedder TF: Introduction: responseregulators of B lymphocyte signaling thresholds provide a context for antigen receptor signal transduction. Sem Immunol 1998;10:259-265.
106. Kurosaki T: Regulation of B- cell signal transduction by adaptor proteins. Nature Reviews 2002;2:354-363.
107. Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF: CD19- regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997;186:1923-1931.
108. Nishizumi H, Taniuchi I, Yamanashi Y, et al: Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn- deficient mice. Immunity 1995;3:549-560.
109. Saito E, Fujimoto M, Hasegawa M, et al: CD19- dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight- skin mouse. J Clin Invest 2002;109:1453-1462.
110. Tsui HW, Siminovitch KA, de Souza L, Tsui FW: Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 1993;4:124-129.
111. Mary C, Laporte C, Parzy D, et al: Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus- prone mice. J Immunol 2000;165:2987-2996.
112. Nitschke L, Lajaunias F, Moll T, et al: Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupusprone mice affects ligand binding. Int Immunol 2006;18:59-68.
113. Sato S, Miller AS, Inaoki M, et al: CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22- deficient mice. Immunity 1996;5:551-562.
114. OKeefe TL, Williams GT, Batista FD, Neuberger MS: Deficiency in CD22, a B cell- specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999;189:1307-1313.
115. Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF: Modulation of B lymphocyte antigen receptor signal transduction by a CD19/ CD22 regulatory loop. Immunity 1999;11:191-200.
116. Mihara M, Tan I, Chuzhin Y, et al: CTLA4Ig inhibits T cell- dependent B- cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106:91-101.
117. Schiffer L, Sinha J, Wang X, et al: Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003;171:489-497.
118. Linterman MA, Rigby RJ, Wong R, et al: Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS. Immunity 2009;30:228-241.
119. Mackay F, Mackay CR: The role of BAFF in B- cell maturation, T- cell activation and autoimmunity. Trends Immunol 2002;23:113-115.
120. Mackay F, Browning JL: BAFF: a fundamental survival factor for B cells. Nature Reviews 2002;2:465-475.
121. Gross JA, Johnston J, Mudri S, et al: TACI and BCMA are receptors for a TNF homologue implicated in B- cell autoimmune disease. Nature 2000;404:995-999.
122. Khare SD, Sarosi I, Xia XZ, et al: Severe B cell hyperplasia and autoimmune disease in TALL- 1 transgenic mice. Proc Natl Acad Sci USA 2000;97:3370-3375.
123. Jacob CO, Pricop L, Putterman C, et al: Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus- prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol 2006;177:2671-2680.
124. Klinman DM: Polyclonal B cell activation in lupus- prone mice precedes and predicts the development of autoimmune disease. J Clin Invest 1990;86:1249-1254.
125. Mohan C, Shi Y, Laman JD, Datta SK: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470-1480.
126. Merino R, Iwamoto M, Fossati L, Izui S: Polyclonal B cell activation arises from different mechanisms in lupus- prone (NZB x NZW)F1 and MRL/MpJ- lpr/lpr mice. J Immunol 1993;151:6509-6516.
127. Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus- like autoimmune diseases by disruption of the PD- 1 gene encoding an ITIM motif- carrying immunoreceptor. Immunity 1999;11:141-151.
128. Haraldsson MK, Louis- Dit- Sully CA, Lawson BR, et al: The lupus- related Lmb3 locus contains a diseasesuppressing Coronin- 1A gene mutation. Immunity 2008;28:40-51.
129. Drappa J, Kamen LA, Chan E, et al: Impaired T cell death and lupus- like autoimmunity in T cell- specific adapter protein- deficient mice. J Exp Med 2003;198:809-821.
130. Zhang Y, Schlossman SF, Edwards RA, Ou CN, Gu J, Wu MX: Impaired apoptosis, extended duration of immune responses, and a lupus- like autoimmune disease in IEX- 1- transgenic mice. Proc Natl Acad Sci USA 2002;99:878-883.
131. Fairhurst AM, Xie C, Fu Y, et al: Type I interferons produced by resident renal cells may promote end- organ disease in autoantibody- mediated glomerulonephritis. J Immunol 2009;183:6831-6838.
132. Seery JP, Carroll JM, Cattell V, Watt FM: Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med 1997;186:1451-1459.
133. Nacionales DC, Kelly- Scumpia KM, Lee PY, et al: Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007;56:3770-3783.
134. Jorgensen TN, Roper E, Thurman JM, Marrack P, Kotzin BL: Type I interferon signaling is involved in the spontaneous development of lupuslike disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice. Genes immune 2007;8:653-662.
135. Ramanujam M, Kahn P, Huang W, et al: Interferon- alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis Rheum 2009;60:1096-1101.
136. Perez de Lema G, Maier H, Franz TJ, et al: Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus- prone mice. J Am Soc Nephrol 2005;16:3592-3601.
137. Steinmetz OM, Turner JE, Paust HJ, et al: CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J Immunol 2009;183:4693-4704.
138. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi- Joannopoulos K: IL- 21 has a pathogenic role in a lupus- prone mouse model and its blockade with IL- 21R. Fc reduces disease progression. J Immunol 2007;178:3822-3830.
139. Dang H, Geiser AG, Letterio JJ, et al: SLE- like autoantibodies and Sjogrens syndrome- like lymphoproliferation in TGF- beta knockout mice. J Immunol 1995;155:3205-3212.
140. Menke J, Rabacal WA, Byrne KT, et al: Circulating CSF- 1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J Am Soc Nephrol 2009;20:2581-2592.
141. Kuroiwa T, Iwasaki T, Imado T, Sekiguchi M, Fujimoto J, Sano H. Hepatocyte growth factor prevents lupus nephritis in a murine lupus model of chronic graft- versushost disease. Arthritis Res Ther 2006;8:R123.